Myelin is produced by oligodendrocytes in the CNS, and its role in propagation of the action potential along the axon has been well studied. Myelin is an extension of the glial cell's plasma membrane, however it is biochemically very different. Part of this difference can be attributed to the composition of the proteins specifically targeted to the myelin membrane. One of these proteins, the myelin proteolipid protein (PLP) accounts for almost 50% of the total protein found in adult CNS myelin. Expression of the gene is tightly regulated. In humans, mutations in the P/p gene (which resides on the X chromosome) have been shown to be associated the X-linked dysmyelinating disorder Pelizaeus-Merzbacher disease (PMD), and some types of spastic paraplegia (SPG-2). Dysmyelination can arise from either elevated levels of P/p gene expression or lack of expression. Thus accurate expression of the P/p is critical, and elucidation of its regulation will be helpful in deciphering essential transcription regulatory elements that may be mutated in some people with PMD/SPG-2. On the other hand, elucidation of the mechanisms whereby the gene is regulated could provide insight into alternative causes of PMD/SPG-2, which do not arise from P/p gene mutations. ? ? Furthermore, it is important to understand how the gone is regulated, in order to help promote the remyelination process in people with demyelinating diseases. Multiple sclerosis, the most common demyelinating disease, generally occurs in adults substantially after the active myelination period in CNS development has ended. A deletion-transfection analysis has confirmed the importance of regulatory sequences located within the first intron that are essential for regulating P/p gone expression. One of these elements, the so-called ASE, for antisilencer/enhancer, appears to cause a dramatic increase in P/p gene expression during (and after) the myelination period of CNS development. We believe that multiple factors assemble on the ASE to form a stereospecific nucleoprotein structure termed an """"""""enhanceosome."""""""" To understand how the ASE mediates P/p gone activation, the following specific aims have been proposed: 1) Characterize further the ASE, a positive cis-acting regulatory element located in intron 1 DNA, which promotes high levels of P/p gene expression in oligodendrocytes; 2) Identify the nuclear factors, which form a transcriptional regulatory complex on the ASE; 3) Elucidate the mechanism whereby the ASE nucleoprotein complex activates P/p gone expression in oligodendrocytes. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS037821-07
Application #
6856499
Study Section
Molecular, Cellular and Developmental Neurosciences 2 (MDCN)
Program Officer
Utz, Ursula
Project Start
1998-07-15
Project End
2007-02-28
Budget Start
2005-03-01
Budget End
2006-02-28
Support Year
7
Fiscal Year
2005
Total Cost
$266,289
Indirect Cost
Name
University of Arkansas for Medical Sciences
Department
Physiology
Type
Schools of Medicine
DUNS #
122452563
City
Little Rock
State
AR
Country
United States
Zip Code
72205
Hamdan, Hamdan; Patyal, Pankaj; Kockara, Neriman T et al. (2018) The wmN1 enhancer region in intron 1 is required for expression of human PLP1. Glia :
Wight, Patricia A (2017) Effects of Intron 1 Sequences on Human PLP1 Expression: Implications for PLP1-Related Disorders. ASN Neuro 9:1759091417720583
Hamdan, Hamdan; Kockara, Neriman T; Jolly, Lee Ann et al. (2015) Control of human PLP1 expression through transcriptional regulatory elements and alternatively spliced exons in intron 1. ASN Neuro 7:
Pereira, Glauber B; Meng, Fanxue; Kockara, Neriman T et al. (2013) Targeted deletion of the antisilencer/enhancer (ASE) element from intron 1 of the myelin proteolipid protein gene (Plp1) in mouse reveals that the element is dispensable for Plp1 expression in brain during development and remyelination. J Neurochem 124:454-65
Zolova, Olga E; Wight, Patricia A (2011) YY1 negatively regulates mouse myelin proteolipid protein (Plp1) gene expression in oligodendroglial cells. ASN Neuro 3:
Pereira, Glauber B; Dobretsova, Anna; Hamdan, Hamdan et al. (2011) Expression of myelin genes: comparative analysis of Oli-neu and N20.1 oligodendroglial cell lines. J Neurosci Res 89:1070-8
Li, Shenyang; Greuel, Brian T; Meng, Fanxue et al. (2009) Leydig cells express the myelin proteolipid protein gene and incorporate a new alternatively spliced exon. Gene 436:30-6
Dobretsova, Anna; Johnson, Jennifer W; Jones, Richard C et al. (2008) Proteomic analysis of nuclear factors binding to an intronic enhancer in the myelin proteolipid protein gene. J Neurochem 105:1979-95
Wight, Patricia A; Duchala, Cynthia S; Shick, H Elizabeth et al. (2007) Expression of a myelin proteolipid protein (Plp)-lacZ transgene is reduced in both the CNS and PNS of Plp(jp) mice. Neurochem Res 32:343-51
Meng, Fanxue; Zolova, Olga; Kokorina, Natalia A et al. (2005) Characterization of an intronic enhancer that regulates myelin proteolipid protein (Plp) gene expression in oligodendrocytes. J Neurosci Res 82:346-56

Showing the most recent 10 out of 16 publications